🇺🇸 FDA
Pipeline program

Replagal (agalsidase alfa)

HGT-REP-084

Phase 2 mab completed

Quick answer

Replagal (agalsidase alfa) for Fabry Disease is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Fabry Disease
Phase
Phase 2
Modality
mab
Status
completed

Clinical trials